Optional loading dose:
Children 8-11 years: 2.4 mg/kg/DAY IV divided q12h, MAX 100 mg/DAY
Children 12 years or older: 2 mg/kg/DAY divided q12h, Max 100 mg/DAY
Safety and efficacy of tigecycline in neonates has not been established, therefore dosages are not available.
Requires dose reduction in severe hepatic impairment; consult a pharmacist for dosage adjustment.
Avoid use in children < 8 years due to adverse effects on tooth development.
Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility
Associated with more treatment failures than alternatives and excess mortality - Black Box Warning
Tetracycline related adverse events: photosensitivity, acute pancreatitis, increased BUN, acidosis, hypophosphatemia, rash (can be severe), abnormal hepatic enzymes and/or function tests.
Permanent tooth discoloration in children < 8 years old.
Recommended Infectious Disease consult.
Documented safety concerns (increaed mortality in adult studies).
Antimicrobial class: Tetracycline derivative
Average serum half life:
No pediatric data
Route of Elimination: 22% excreted in urine as unchanged drug; 59% in feces, primarily as unchanged drug
Clearance: Reduced by 25% in patient with moderate hepatic impairment and 55% in severe hepatic impairment